Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label etelcalcetide in hemodialysis patients with secondary hyperparathyroidism
jRCT2080222614Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Ono Pharmaceutical. Primary endpoint: Long-term safety of etelcalcetide. Started Sep 2014; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080222614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222614.